Cargando…

Long‐term real‐life adherence of percutaneous tibial nerve stimulation in over 400 patients

BACKGROUND: Percutaneous tibial nerve stimulation (PTNS) is used as a treatment to reduce the complaints of overactive bladder (OAB). Although it is rewarding therapy patients need maintenance treatment to preserve the beneficial effect. AIM: This real‐life retrospective study was performed to asses...

Descripción completa

Detalles Bibliográficos
Autores principales: te Dorsthorst, Manon J., Heesakkers, John P. F. A., van Balken, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027784/
https://www.ncbi.nlm.nih.gov/pubmed/31845404
http://dx.doi.org/10.1002/nau.24254
_version_ 1783498904782766080
author te Dorsthorst, Manon J.
Heesakkers, John P. F. A.
van Balken, Michael R.
author_facet te Dorsthorst, Manon J.
Heesakkers, John P. F. A.
van Balken, Michael R.
author_sort te Dorsthorst, Manon J.
collection PubMed
description BACKGROUND: Percutaneous tibial nerve stimulation (PTNS) is used as a treatment to reduce the complaints of overactive bladder (OAB). Although it is rewarding therapy patients need maintenance treatment to preserve the beneficial effect. AIM: This real‐life retrospective study was performed to assess the feasibility of PTNS adherence. MATERIALS & METHODS: All patients who underwent PTNS were retrospectively included. We analyzed the following: indication, kind of treatments (pharmacologic and third‐line therapy) before and after PTNS treatment, time and reason for quitting therapy. Statistical analysis was done by performing competitive‐risk analysis and Kaplan‐Meier curves. Patients were categorized into four groups. Group 1: all patients; group 2: all patients on maintenance PTNS therapy (continuing after 12 weeks); group 3: patients on maintenance PTNS therapy excluding the following: (a) patients with initial good response who seized treatment due to death, (b) patient who successfully switched to transcutaneous stimulation, (c) patients who were cured of their OAB symptoms, or (d) patients who relocated; and group 4: group 3 but excluding those who stopped treatment because of nonmedical reasons (physical strain, inconveniencies associated with visiting the hospital). RESULTS: Four‐hundred two patients (70% female) with a median age of 70 years underwent PTNS. Underlying treatment indications were: OAB‐wet (54%) and OAB‐dry (29%). The median follow‐up (FU) of group 1 was 4 months. Fifty‐seven percent (N = 228) of the patients received maintenance PTNS therapy. Median FU in group 4 was 46 months (range, 3‐111 months). Over 40% of the maintenance patients stopped PTNS because of logistic reasons and physical strain during an FU time of 6 years. CONCLUSION: The real‐world data described here with is in line with earlier published work in terms of the success rate of OAB treatment. However, over 40% quit their therapy due to nonmedical reasons.
format Online
Article
Text
id pubmed-7027784
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70277842020-02-24 Long‐term real‐life adherence of percutaneous tibial nerve stimulation in over 400 patients te Dorsthorst, Manon J. Heesakkers, John P. F. A. van Balken, Michael R. Neurourol Urodyn Original Clinical Articles BACKGROUND: Percutaneous tibial nerve stimulation (PTNS) is used as a treatment to reduce the complaints of overactive bladder (OAB). Although it is rewarding therapy patients need maintenance treatment to preserve the beneficial effect. AIM: This real‐life retrospective study was performed to assess the feasibility of PTNS adherence. MATERIALS & METHODS: All patients who underwent PTNS were retrospectively included. We analyzed the following: indication, kind of treatments (pharmacologic and third‐line therapy) before and after PTNS treatment, time and reason for quitting therapy. Statistical analysis was done by performing competitive‐risk analysis and Kaplan‐Meier curves. Patients were categorized into four groups. Group 1: all patients; group 2: all patients on maintenance PTNS therapy (continuing after 12 weeks); group 3: patients on maintenance PTNS therapy excluding the following: (a) patients with initial good response who seized treatment due to death, (b) patient who successfully switched to transcutaneous stimulation, (c) patients who were cured of their OAB symptoms, or (d) patients who relocated; and group 4: group 3 but excluding those who stopped treatment because of nonmedical reasons (physical strain, inconveniencies associated with visiting the hospital). RESULTS: Four‐hundred two patients (70% female) with a median age of 70 years underwent PTNS. Underlying treatment indications were: OAB‐wet (54%) and OAB‐dry (29%). The median follow‐up (FU) of group 1 was 4 months. Fifty‐seven percent (N = 228) of the patients received maintenance PTNS therapy. Median FU in group 4 was 46 months (range, 3‐111 months). Over 40% of the maintenance patients stopped PTNS because of logistic reasons and physical strain during an FU time of 6 years. CONCLUSION: The real‐world data described here with is in line with earlier published work in terms of the success rate of OAB treatment. However, over 40% quit their therapy due to nonmedical reasons. John Wiley and Sons Inc. 2019-12-17 2020-02 /pmc/articles/PMC7027784/ /pubmed/31845404 http://dx.doi.org/10.1002/nau.24254 Text en © 2019 The Authors. Neurourology and Urodynamics published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Clinical Articles
te Dorsthorst, Manon J.
Heesakkers, John P. F. A.
van Balken, Michael R.
Long‐term real‐life adherence of percutaneous tibial nerve stimulation in over 400 patients
title Long‐term real‐life adherence of percutaneous tibial nerve stimulation in over 400 patients
title_full Long‐term real‐life adherence of percutaneous tibial nerve stimulation in over 400 patients
title_fullStr Long‐term real‐life adherence of percutaneous tibial nerve stimulation in over 400 patients
title_full_unstemmed Long‐term real‐life adherence of percutaneous tibial nerve stimulation in over 400 patients
title_short Long‐term real‐life adherence of percutaneous tibial nerve stimulation in over 400 patients
title_sort long‐term real‐life adherence of percutaneous tibial nerve stimulation in over 400 patients
topic Original Clinical Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027784/
https://www.ncbi.nlm.nih.gov/pubmed/31845404
http://dx.doi.org/10.1002/nau.24254
work_keys_str_mv AT tedorsthorstmanonj longtermreallifeadherenceofpercutaneoustibialnervestimulationinover400patients
AT heesakkersjohnpfa longtermreallifeadherenceofpercutaneoustibialnervestimulationinover400patients
AT vanbalkenmichaelr longtermreallifeadherenceofpercutaneoustibialnervestimulationinover400patients